HDFC Mutual Fund · Direct Growth · SEBI Category: Equity
HDFC Pharma and Healthcare Fund is backed by India's largest AMC — HDFC Mutual Fund — bringing institutional research depth to pharmaceutical and healthcare sector investing. The fund invests across the healthcare value chain: pharmaceutical manufacturers, API companies, hospitals, diagnostic chains and medical devices. HDFC MF's conservative investment culture means the portfolio emphasises business quality and regulatory track record over aggressive growth at any price.
The fund's approach reflects HDFC MF's broader investment philosophy — quality businesses with strong balance sheets, capable management and sustainable competitive advantages. In the pharma sector, this translates to companies with clean FDA records, diversified revenue streams (multiple geographies and therapy areas) and management teams with proven integrity. Avoiding regulatory risk is as important as identifying growth opportunities.
Srinivasan Ramamurthy is Fund Manager at HDFC Mutual Fund and manages HDFC Pharma and Healthcare Fund alongside his other equity mandates. He applies HDFC MF's research-intensive, fundamental analysis approach to healthcare sector investing — focusing on the quality of the business, regulatory compliance track record, management integrity and long-term competitive positioning of healthcare companies across the value chain.
For current co-manager details and full biography, refer to the latest HDFC Mutual Fund factsheet on AMFI or the AMC website.
Informational points to help you form your own view — not judgements or recommendations.
Live data. Current fund highlighted. Click any fund name for full analysis.
| Fund | NAV | AAUM | 1Y Return | 3Y CAGR | 5Y CAGR | Sharpe (3Y) |
|---|---|---|---|---|---|---|
| Nippon India Pharma Fund | ₹596.02 | ₹7.9K Cr Jan–Mar 2026 | +5.9% | +22.5% p.a. | +13.4% p.a. | 1.37 |
| SBI Healthcare Opportunities Fund | ₹532.86 | ₹3.8K Cr Jan–Mar 2026 | +10.5% | +25.5% p.a. | +16.2% p.a. | 1.61 |
| DSP Healthcare Fund | ₹46.10 | ₹3.0K Cr Jan–Mar 2026 | +8.8% | +22.9% p.a. | +15.4% p.a. | 1.62 |
| Mirae Asset Healthcare Fund | ₹47.02 | ₹2.7K Cr Jan–Mar 2026 | +13.9% | +25.8% p.a. | +15.6% p.a. | 1.45 |
| HDFC Pharma and Healthcare Fund ▲ | ₹20.01 | ₹1.9K Cr Jan–Mar 2026 | +19.9% | — | — | — |
Calculated from 655 daily NAV records in RightAdvise DB. Last calculated: Jun 2026.
1M / 3M / 6M / 1Y — simple point-to-point return · 3Y / 5Y / 10Y — CAGR (compounded annual growth rate)
Based on all rolling windows in full NAV history. Dates show the start and end of each period.
Jan 1 to Dec 31 each year. Simple point-to-point — not CAGR.
Rolling returns show performance across every possible investment start date — not one cherry-picked number. Learn more →
How much the fund fell from its peak NAV — what investors actually experience during crashes. Calculated from full NAV history.
Calculated from actual NAV data. "Pre-inception" means the fund didn't exist during that period.
Calculated from 3 years of daily NAV — industry standard. Risk-free rate: 6.5% p.a. Last updated: Jun 2026. What do these mean? →
Our portfolio holdings page shows every stock the fund owns, sector allocation, and month-over-month changes — from official AMC disclosures.
See how HDFC Pharma and Healthcare FundOption ranks against other Equity funds on returns, drawdown, Sharpe ratio and AAUM — side by side.
New fund analysis, articles and market insights — no spam, no selling. Unsubscribe anytime.
Found this useful? Share it
Found an error? Have a suggestion? We read every response.